Immune checkpoint inhibitor-induced neurotoxicity is not associated with seroprevalence of neurotropic infections.

Publication

Immune checkpoint inhibitor-induced neurotoxicity is not associated with seroprevalence of neurotropic infections.

Journal Paper/Review - Aug 22, 2023

Schmitt Christina, Hoefsmit E P, Fangmeier T, Kramer N, Kabakci C, González-Navajas Jose M, Versluis Judith M, Compter Annette, Harrer T, Mijočević H, Schubert Steffen, Hundsberger Thomas, Menzies A M, Scolyer Richard A, Long Georgina V, French Lars Einar, Blank Christian U, Heinzerling Lucie M

Citation

Schmitt C, Hoefsmit E, Fangmeier T, Kramer N, Kabakci C, González-Navajas J, Versluis J, Compter A, Harrer T, Mijočević H, Schubert S, Hundsberger T, Menzies A, Scolyer R, Long G, French L, Blank C, Heinzerling L. Immune checkpoint inhibitor-induced neurotoxicity is not associated with seroprevalence of neurotropic infections. Cancer Immunol Immunother 2023

Type

Journal Paper/Review (English)

Journal

Cancer Immunol Immunother 2023

Publication Date

Aug 22, 2023

Issn Electronic

1432-0851

Brief description/objective

Immune checkpoint inhibitors (ICI) substantially improve outcome for patients with cancer. However, the majority of patients develops immune-related adverse events (irAEs), which can be persistent and significantly reduce quality of life. Neurological irAEs occur in 1-5% of patients and can induce severe, permanent sequelae or even be fatal. In order to improve the diagnosis and treatment of neurological irAEs and to better understand their pathogenesis, we assessed whether previous neurotropic infections are associated with neurological irAEs.